Eris Lifesciences is set to debut on the stock market tomorrow after concluding its initial public offer last week.

COMMERCIAL BREAK
SCROLL TO CONTINUE READING

The company's IPO was oversubscribed 3.29 times during June 16-20.

The portion set aside for qualified institutional buyers (QIBs) was oversubscribed 4.68 times, non institutional investors 45 per cent and retail investors 3.51 times.

The price band for the share sale was fixed at Rs 600- 603.

The book running lead managers to the offer were Axis Capital, Citigroup Global Markets India and Credit Suisse Securities (India).

Eris Lifesciences is into manufacturing of branded pharmaceutical products in select therapeutic areas.

(This article has not been edited by DNA's editorial team and is auto-generated from an agency feed.)